2017 Speakers

Dr. Laleh Amiri-Kordestani, MD

Medical Officer, Division of Oncology Products 1, Food and Drug Administration, Centre for Drug Evaluation and Research, Silver Spring, MD, USA

founder

Laleh Amiri-Kordestani, M.D. is a clinical team leader and cardio-oncology liaison at the FDA, CDER, Office of Hematology and Oncology Products. At the FDA, Dr. Amiri has focused on cardio-oncology and breast cancer oncology drug development. Dr. Amiri attended the University of Tehran Medical Sciences.

Co-Chair: Session 7 - Cardio-Oncology & Heamato-Oncology

Read More...

She did a year of post-doctoral research fellowship in Molecular Genetics Laboratory at NIH and went on to study internal medicine at the Georgetown University/Washington Hospital Center and completed her medical oncology and hematology fellowship at the National Cancer Institute (NCI) in Bethesda, MD. In addition, she pursued an M.S. degree in Clinical Research in the Joint Program of the National Cancer Institute and Duke University. Under the direction of Dr. Sandra Swain, she became familiar with the design and implementation of oncology clinical trials and at the NCI she worked with Dr. Susan Bates focusing on early phase clinical trials. Dr. Amiri remains clinically active, treating breast cancer patients at NCI and practicing inpatient medicine at Georgetown University Hospital.

Dr. Ana Barac, MD, PhD, FACC

Noninvasive Cardiologist; Director of the Cardio-Oncology Program, MedStar Heart and Vascular Institute; Assistant Professor of Medicine, Georgetown University, Washington, DC, USA

founder

Ana Barac, MD, PhD, is a noninvasive cardiologist at MedStar Heart and Vascular Institute and an Assistant Professor of Medicine at Georgetown University. Her clinical and research interests focus on the mechanisms, diagnosis and treatment of cardiac complications of cancer therapies and she leads MedStar Heart and Vascular Institute’s Cardio-Oncology program.

Co-Chair: Session 5 - Coordinating Primary Care in Cardio-Oncology

Read More...

Dr. Barac has basic science research background in signaling pathways and in vascular physiology research on endothelial function. She previously was a research fellow at the National Institute of Dental and Craniofacial Research, National Institutes of Health. She holds KL2 Scholar Award from the Georgetown-Howard Universities Center for Clinical and Translational Science for investigations of cardiovascular toxicity in patients with breast cancer. Her clinical cardiac imaging expertise includes advanced training in cardiac MR and echocardiography. Dr. Barac led the Cardio-Oncology Working group within the American College of Cardiology (ACC) and was appointed chair of the new ACC Cardio-Oncology Council in 2015. She serves on the editorial boards of the Journal of the American College of Cardiology (JACC), the Journal of Cardiovascular Translational Research and the Cardio-Oncology journal.

Dr. Anne Blaes, MD, MS

Associate Professor, Division of Hematology/Oncology/Transplant; Program Director, Cancer Survivor Program, University of Minnesota, Minneapolis, MN, USA

founder

Dr. Blaes graduated from the University of Notre Dame and then received her M.D. degree from Loyola University Chicago, Stritch School of Medicine. She performed her residency at the University of Minnesota, where she was named the Resident Teacher of the Year and received the Gold Foundation Humanism and Excellence in Teaching Award for her outstanding contributions as a resident role model.

Conference Topic: Session 3 - Novel pathophysiology of cardiovascular risk with estrogen antagonists

Read More...

She served as Chief Resident in Internal Medicine and then subsequently completed a Hematology and Oncology fellowship and a Master of Science in Clinical Research degree at the University of Minnesota, prior to joining the faculty. Dr. Blaes has a special interest in cancer survivorship, the late effects of cancer therapy, and medical education. Her research interests, funded by a BIRCWH award, include quality of life, cardiac complications of chemotherapy, and the late effects of cancer therapy in cancer survivors, particularly breast and colorectal cancer survivors. In addition to mentoring medical students and residents on research projects, she teaches the Blood pathophysiology course and the Human Diseases IV course within the medical school. She received an Educational Excellence Award from the Department of Medicine in 2010, and has been named to Minnesota Monthly’s Best Doctors for Women in 2011 and 2012.

Prof. Jutta Bergler-Klein, MD, FESC

Professor of Medicine and Cardiology; Head of Cardiac Outpatients and Acute first care unit; Vice Head, Day Clinic; Senior Consultant Cardiology Dept. of Cardiology, University Clinic of Internal Med. II, Medical University of Vienna, AKH General Hospital, Vienna, Austria

Conference Topic: Session 4 - Case Review

Dr. Daniela Cardinale, MD, PhD

Cardioncology Unit Director, European Institute of Oncology, Milan, Italy

founder

Dr. Daniela Cardinale graduated from the University of Milan in 1987 and specialized in Cardiology (Milan 1992). She holds a PhD in Cardiovascular Physiopathology from the same University (2009). She is currently Director of the Cardioncology Unit of the European Institute of Oncology in Milan, where she has been working since 1994.

Co-Chair: Session 6 - Young Investigator Competition

Read More...

She has previously worked at the Operative Unit of Intensive Cardiac Care of the Centro Cardiologico Monzino (1987-1990) and at the Cardiology Division of S. Raffaele Hospital of Milan (1990-1994). Her professional experience and investigational interests focus on prevention, early detection, monitoring and treatment of cardiotoxicity; screening of cardiotoxicity in patients with cardiac disease; malignant pericardial effusion evaluation and intrapericardial treatment. Since 2009, she is the Vice-President of the ICOS (International CardiOncology Society). She is a fellow of the European Society of Cardiology.

Dr. John-Paul Carpenter

Consultant Cardiologist, Poole Hospital NHS Foundation Trust, Burley, Hamshire, UK

Co-Chair: Session 9 - Arrhythmia management in cancer patients

Vicki Chambers

Clinical Nurse Specialist Heart Failure, Royal Brompton & Harefield NHS Foundation Trust, London, UK

Conference Topic: Session 10 - The Role of the Clinical Nurse Specialist in Cardio-Oncology

Dr. Sarah Clarke, MA, MD, FRCP, FESC, FACC

Consultant Cardiologist, Papworth Hospital, Cambridge, United Kingdom. President, British Cardiovascular Society.

founder

Dr Sarah Clarke MA MD FRCP FESC FACC, is a Consultant Cardiologist at Papworth Hospital, Cambridge and was elected President of the British Cardiovascular Society (BCS) in 2014, taking up office in June 2015 for a 3 year term. Dr Clarke trained in Cambridge and at the Massachusetts General Hospital in Boston, USA. She was appointed Consultant Cardiologist (Interventional Cardiology) at Papworth Hospital, Cambridge in 2002. 

Co-Chair: Session 1

Read More...

She was Clinical Director for Cardiac Services (2006-2012) and appointed Clinical Director for Strategic Development from 2012. She was cardiology lead for the design of New Papworth Hospital (opening 2018) on the Cambridge Biomedical Campus and is involved in the delivery of the transition programme. She has recently been appointed Clinical Lead for the Elective Care Working Group for the Cambridge and Peterborough CCG System Transformation Programme (includes cardiology, ophthalmology, orthopaedics and ENT). Dr Clarke is the Clinical Lead for the Cardiovascular Clinical Study Group at the Eastern Academic Health Science Network. She is the international editor of the e-newsletter of the ACC, a member of the Women in Cardiology Council at the ACC and Series Editor for Education in Heart. Formerly Vice President of Education and Research at the BCS (2011-2014), Dr Clarke reinvigorated the Annual Conference as the 'must go' meeting for general cardiology for trainees and trained cardiologists facing revalidation. She established new courses including the 'Year in Cardiology' held each year at the RCP and serialised in the European Heart Journal 5 years ago, and a course for industry employees to educate in general cardiology and the subspecialties. 

Dr. Sinead Clarke, MBChB, MRCGP

General Practitioner Nantwich Health Centre NHS Foundation Trust; Primary Care End of Life Lead, Cheshire and Merseyside Clinical Network; GP Advisor Manchester and Cheshire, Macmillan Cancer Support, Nantwich, UK

Conference Topic: Session 5 - Raising Awareness of cardiotoxicity in primary care

Prof. Jane Dacre, MD, PRCP

President, Royal College of Physicians, London, UK

founder

Professor Jane Dacre was elected president of the Royal College of Physicians in April 2014. She is an honorary consultant physician and rheumatologist at the Whittington hospital in North London, Professor of Medical Education and was Director of UCL Medical School in London before taking a secondment to become PRCP. Professor Dacre was also the medical director of MRCPUK until December 2013 and prior to that academic vice president of the RCP.

Conference Topic: Day 2 - Opening Address

Read More...

Professor Dacre is a vice chair of the Academy of Medical Royal Colleges, was a GMC council member, and chaired the GMC education and training Committee (2008-2012) and leads a research programme in medical education focussing on assessment. Professor Dacre was the clinical lead for the development of the first Clinical Skills Centre in the UK, and was a co-author of the GALS screen. She has been instrumental in the development, implementation and evaluation of assessment systems in medicine. Professor Dacre won the medicine and healthcare category for the 2012 Women in the City Woman of Achievement Award; was named on the Health service journal’s inaugural list of 50 inspirational women in healthcare in 2013; was named in the science and medicine category for people of influence Debrett’s 500 in 2015, 2016 and 2017; and was named on the Health service journal’s top 100 list in both 2014 and 2015.

Prof. Sarah Darby

Professor of Medicine Statistics, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, England

founder

Sarah C Darby is Professor of Medical Statistics in the University of Oxford.  She studied for her PhD at the London School of Hygiene and Tropical Medicine. She then worked at St. Thomas’ Hospital Medical School, the National Radiological Protection Board, and the Radiation Effects Research Foundation in Hiroshima before moving to Oxford.

Conference Topic: Session 4 - Scale of radiation-induced cardiovascular disease in cancer survivors

Read More...

Sarah is a member of the secretariat of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), which carries out meta-analyses of individual patient data from randomised controlled trials of various treatments for breast cancer, and she leads the EBCTCG analyses of the effects of radiotherapy and surgery. In addition, she leads a number of studies to evaluate the long-term risk of heart disease and other serious side-effects from cancer treatments and she works on several studies to evaluate the risk of cancer from exposure to ionising radiation.

Dr. Susan Dent, MD, FRCPC

President, Canadian Cardiac Oncology Network; Medical Oncologist, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

founder

Dr. Dent is a Medical Oncologist at The Ottawa Hospital Cancer Centre and Associate Professor in the Department of Medicine at the University of Ottawa.  She obtained her MD at McMaster University and completed her postgraduate training in Internal Medicine at the University of Ottawa. She continued her training in Medical Oncology in Ottawa, followed by a fellowship year in Clinical Research with the National Cancer Institute of Canada Clinical Trials Group.

Co-Chair: Session 1

Read More...

She is the research lead for the breast disease site group at the Ottawa Hospital Cancer Centre, and a member of the IND working group for the Breast Cancer Disease Site Committee of the National Cancer Institute for Canada Clinical Trials Group. Her areas of research interest include breast cancer, and treatment related toxicities with a particular interest in cardiotoxicity. She is the founder of the Ottawa Cardiac Oncology Program as well as the Canadian Cardiac Oncology Network, organizations dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity.

Dr. Martin Denvir

Consultant Cardiologist, University of Edinburgh, Edinburgh, UK

Conference Topic: Session 4 - How to treat radiation-induced coronary disease? Prevention & Treatment

Prof. Helena Earl

Professor of Clinical Cancer Medicine; Honorary Consultant Medical Oncologist, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

founder

Professor Helena Earl completed a PhD in Breast Cancer in 1985 and specialist training in Medical Oncology with General Internal Medicine at UCLH in 1991. In 1992 she joined the University of Birmingham and was Director of the Cancer Research UK Clinical Trials Unit, moving to the University of Cambridge, Department of Oncology in 1996. She is active in clinical and translational research and leads NCRN clinical trials in breast cancer (NEAT, tAnGo, Neo-tAnGo, ARTemis, PERSEPHONE, and PARTNER). 

Co-Chair: Day 1 - Plenary Lecture

Read More...

Professor Earl holds grant funding from Cancer Research UK, the NIHR HTA, and pharmaceutical partners. She is a PI in the Cancer Research UK Cambridge Cancer Centre, NIHR BRC, ECMC, CCTC, and Cambridge Breast Cancer Research Unit. She is an active member of the Cambridge Trials Methodology Group developing linked Bayesian Adaptive Randomised (BAR) designs, with biomarkers and new treatments, integrating early biomarkers of response into these designs. Professor Earl has published her research in cardio-oncology from the PERSEPHONE Trial of adjuvant trastuzumab duration.

Prof. Sara Faithfull

Professor of Cancer Nursing Practice, Lead for Clinical Innovation, University of Surrey, Surrey, UK

Conference Topic: Session 5 - Managing cardiovascular risk in cancer patients in primary care

Dr. Dimitrios Farmakis

Cardiologist, Thalassemia and Transfusion Unit, Ippokrateion General Hospital, Athens, Greece

Conference Topic: Session 9 - Practical matters in atrial fibrillation - anticoagulation & rhythm management

Dr. John Groarke

Cardiovascular Medicine Specialist, Brigham and Women's Hospital; Cardio-Oncologist, Dana Farber Cancer Institute, Boston, MA, USA

Conference Topic: Session 4 - Radiation-induced autonomic dysfunction and arrhythmias

Dr. Mark Harbinson

Consultant Cardiologist, Queen's University Belfast, Belfast, Northern Ireland, UK

Co-Chair: Session 4 - Radiation therapy and long-term cardiovascular complications

Prof. Sian Harding

Professor of Cardiac Pharmacology, National Heart and Lung Institute, Imperial College, London, UK

Conference Topic: Session 8 - iPSC models to study cardiotoxicity

Dr. Eric Harrison, MD

Medical Director, Tampa Memorial Hospital;, Cardiologist, Harrison Cardiovascular Centre, Tampa, FL, USA

founder

Dr. Harrison is currently the National Director of Advanced Cardiac Imaging of Iasi Healthcare Inc .  which owns and operates 15 acute care hospitals in  Florida, Texas, Louisiana,  Utah, Arizona, and Nevada. Dr. Harrison was one of first to use the therapeutic hypothermia for Cardiac Arrest patients. He began to use this treatment clinically shortly after the landmark articles were published in February 2002.

Co-Chair: Session 7 - Cardio-Oncology and Haemato-Oncology

Read More...

He is currently integrating hypothermic medicine into the IASIS healthcare system. He has served as a consultant for many national companies associated with cardiac imaging. Dr. Harrison started and directs the Joint Memorial Hospital / University of South Florida Medical School Advanced Cardiac Imaging Program for practicing  physicians , cardiac fellows, and medical student training. He is a preceptor for the University of South Florida Medical School and Saba University Medical School of the  Netherland Antilles. Dr. Harrison received his medical degree from the University of Kentucky and completed internship, Internal Medicine residency and Cardiology Fellowship at the University of South Florida  where he was a Special Fellow of the Florida Heart Association. He was acting Director of the Cath Lab at the VA Hospital  for 3 month prior to finishing his training. He is a founding physician of the University of South Florida Medical School. Dr. Harrison's experience in cardiology covers a broad spectrum. He was co-director of the Cardiology Center at Tampa General Hospital for thirteen years and directed noninvasive cardiology for seven years where he started echocardiography and nuclear cardiology. At Tampa General he performed over 14,000 heart catheterizations, numerous coronary angioplasties, cardiac electrophysiologic studies and myocardial biopsies and was a transplant cardiologist on the transplant team for three years. His first transplant patient has survived  over 20 years. He and his colleagues started the first outpatient cardiovascular health center in Tampa at Memorial Hospital where he is currently the Medical Director and where he has directed the cardiac rehabilitation program. His non-invasive cardiology interests are 3D echo, multislice CAT scan imaging of the coronaries, Cardiac PET/CT, Cardiac MRI, and hybrid imaging.

Dr. Joerg Herrmann, MD

Associate Professor of Medicine, Mayo Graduate School of Medicine, Rochester, NY

founder

Dr. Joerg Herrmann graduated from Ruhr University medical school in Bochum, Germany and completed his internal medicine residency and cardiovascular diseases and interventional cardiology fellowship at the Mayo Clinic in Rochester, MN. Thereafter, he joined the division of cardiovascular diseases at the Mayo Clinic Rochester, and is an Associate Professor of Medicine at the Mayo Clinic College of Medicine.

Conference Topic: Session 10 - Toolkit for success - real world options

Read More...

He currently serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program. His research interests focus on all aspects of cardio-oncology and the pathophysiology, diagnosis, and treatment of atherosclerosis. He has published over 90 articles in peer-reviewed journals and has received NIH grant funding. He also serves as the associated editor of Trends in Cardiovascular Medicine and PracticeUpdate.

Prof. Denise Hilfiker-Kleiner

Professor of Molecular Cardiology, Hannover Medical School, Hanover, Germany

Conference Topic: Session 8 - New strategies to protect the heart from cancer therapies

Dr. Christopher B. Johnson, MD

Cardiologist, The Ottawa Hospital, Ottawa, ON, Canada

founder

Dr. Johnson obtained his MD (Magna Cum Laude) from the University of Ottawa in 1998. He completed his internal medicine residency and cardiology fellowship at the University of Ottawa before pursuing additional fellowship training in echocardiography and nuclear cardiology at the University of Ottawa Heart Institute. Dr. Johnson is an Assistant Professor of Medicine in the Division of Cardiology at the University of Ottawa.

Co-Chair: Day 1 Plenary Session

Read More...

His hospital practice at the General Campus of the Ottawa Hospital focuses on non-invasive cardiac imaging and clinical cardiology in special populations, including cardio-oncology, and he helped establish Ottawa’s cardio-oncology clinic in 2008. As a clinician educator at the University of Ottawa, Dr. Johnson is active in teaching medical students, residents, and cardiology fellows. He is an Associate Program Director for the Core Internal Medicine Residency Training Program, he sits on a number of local and provincial education committees, and he is regularly invited to speak at conferences related to cardiology education and cardio-oncology.

Dr. Anna Kirby

Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust, London, UK

Co-Chair: Session 4: Radiation therapy and long-term cardiovascular complications

Prof. Mike Kirby

Visiting Professor to the Faculty of Health & Human Sciences, University of Hertfordshire, The University of Bedfordshire, and to the Prostate Centre, Hatfield, Hertfordshire, UK

Conference Topic: Session 5 - Managing cardiovascular risk in cancer patients in primary care

Dr. Bonnie Ky, MD, MSCE

Assistant Professor of Medicine and Epidemiology, Division of Cardiology, University of Pennsylvania School of Medicine, Philadelphia, PA

founder

Dr. Bonnie Ky, MD, MSCE is an Assistant Professor of Medicine and Epidemiology at the University of Pennsylvania School of Medicine Division of Cardiology, a Senior Scholar in the Center for Clinical Epidemiology and Biostatistics, and is the Director of the Penn Center for Quantitative Echocardiography.

Co-Chair: Day 1 Plenary Lecture

Read More...

In this role, she leads a highly active NIH-funded translational research program aimed at identifying the underlying mechanisms and predictors of cancer therapy cardiotoxicity in many populations, including breast, renal cell, lung cancer and lymphoma. Specifically, her study objectives are to determine the role of mechanistic biomarkers and echocardiography-derived measures of myocardial mechanics in understanding and predicting incident cardiotoxicity and adverse cardiovascular outcomes with cancer treatment. She has specialized training in clinical epidemiology, the study of cardiovascular biomarkers, and the use of quantitative echocardiography as tools to understand cardiac remodeling and risk prediction. Dr. Ky received her a Bachelor of Science degree in Chemical Engineering from the Massachusetts Institute of Technology. She received her Doctor of Medicine degree from the University of Pennsylvania School of Medicine. She completed her residency and cardiology fellowship as well as a Masters of Science in Epidemiology at the University of Pennsylvania. She is a member of the American College of Cardiology (Cardio-oncology Council), American Heart Association, American Society of Echocardiography (Cardio-oncology Guidelines Writing Committee), American Society of Clinical Oncology (Cardiac Dysfunction in Survivors Writing Committee), Heart Failure Society of America (Chair, Research Committee), International Cardio-Oncology Society (Director, Scientific Committee), National Cancer Institute (NCI) Community Oncology Cardiotoxicity Task Force, and is an invited member of many cardio-oncology expert consensus groups.

Dr. James Larkin

Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust, London, UK

Conference Topic: Session 2 - The impact of immunotherapy in treating solid tumours

Dr. Daniel Lenihan, MD

President, International CardiOncology Society - North America; Professor of Medicine; Director, Clinical Research Program, Vanderbilt Heart and Vascular Institute, Nashville, TN, USA

founder

Dr. Lenihan, has been active in clinical research in cardiology, and specifically in heart failure, for nearly 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer.

Co-Chair: Session 6 - Young Investigator Competition

Read More...

His current projects include early phase clinical trials in heart failure, including the recently presented Phase 1 trial of GGF2 in cooperation with Acorda, Inc. As the Director of Clinical Research in the Division of Cardiovascular Medicine, Dr Lenihan is managing over 100 clinical trials in conjunction with all of VHVI faculty and continues to enhance and foster collaboration among a host of colleagues both internally and throughout the world. He is the current president (US/Canada) of the International CardiOncology Society, a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Dr. Gill Levitt

Honorary Consultant Oncologist, Great Ormond Street Hospital for Sick Children NHS Foundation Trust, London, UK

Conference Topic: Session 5 - Lessons from paediatric oncology: How to organize long-term cardiovascular surveillance in cancer survivors

Dr. Teresa Lopez-Fernandez, MD

Noninvasive Cardiologist, Cardiac Imaging Unit and Cardio-oncology Unit, La Paz University Hospital, Madrid, Spain

founder

Teresa López-Fernández, MD, is a noninvasive cardiologist in the Cardiac Imaging Unit and Cardio-Oncology Unit, at La Paz University Hospital, Madrid, Spain. Her clinical and research focus include the mechanisms, diagnosis and treatment of cardiac complications of cancer therapies. Her clinical cardiac imaging expertise includes advanced training in echocardiography, 3D echocardiography, and stress echocardiography.

Co-Chair: Session 6 - Young Investigator Competition

Read More...

Dr. López-Fernández is a member of the Spanish Society of Cardiology Cardiac Imaging Board and Cardio oncology working group board. She is also a Task Force Member for the development of a position paper on anticancer treatments and cardiovascular toxicity developed under the auspices of the Committee for Practice Guidelines of the European Society of Cardiology. Dr. López-Fernández obtained her degree in Medicine and Surgery in from the Universidad Complutense de Madrid (Spain) in 1996, followed by an I.R. Residence in Cardiology in the Hospital Fundación Jiménez Díaz, in Madrid (1997-2002). In 2004, she obtained her accreditation in advanced Echocardiography by the Spanish Society of Cardiology. Dr. López-Fernández completed additional certifications in Adult Transthoracic Echocardiography (2013) and Adult Transesophageal Echocardiography (2014) by the European Society of Cardiology.

Dr. Alexander Lyon, MA, BM, BCh, PhD, FRCP

GCOS 2017 Co-Chair; British Heart Failure Foundation Senior Lecturer in Cardiology, Imperial College London; Consultant Cardiologist & Clinical Lead for Cardio-Oncology Service, Royal Brompton Hospital, London, United Kingdom. President of the British Cardio-Oncology Society.

founder

Dr. Alexander Lyon is a British Heart Foundation Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. He studied medicine at Oxford University where he gained a first class degree, and studied for his PhD thesis in myocardial gene therapy at Imperial College London.

GCOS 2017 Co-Chair

Read More...

He continued his gene therapy research during a postdoctoral research year in the laboratory of Roger Hajjar at Mount Sinai Hospital in New York. His clinical interests are in the field of heart failure, cardio-oncology and Takotsubo syndrome, and he is the theme leader for heart failure research in the NIHR-funded Biomedical Research Unit at the Royal Brompton Hospital. He is the clinical lead for the new Cardio-Oncology service at the Royal Brompton hospital, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. He is the president of the British Cardio-Oncology Society and a member of the European Society of Cardiology Taskforce on Cardio-Oncology. He is the clinical advisor to the british cancer patient charity Macmillan Cancer and helped to write the first patient information leaflet – Heart health for Cancer Patients. He is the UK national lead investigator for two gene therapy trials for chronic heart failure (CUPID2 and SERCA-LVAD), and is the heart failure lead for the RDN-HFpEF study assessing the role of renal sympathetic denervation for individuals with heart failure with preserved ejection fraction. He is leading both a laboratory research programme understanding the influence of stress and high catecholamine levels upon myocardial function, and he is coordinating both a national and European strategy to advance knowledge and improve care for individuals with Takotsubo syndrome. He runs a specialist clinic for patients with Takotsubo syndrome focussing on risk prediction and management of refractory symptoms.

Prof. Jane Maher

Consultant Clinical Oncologist, Mount Vernon Cancer Centre and Hillingdon Hospital; Chief Medical Officer, Macmillan Cancer Support, London, UK

Session 1 Keynote Lecture: Cancer survivorship and the impact of cardiovascular disease

Dr. Charlotte Manisty

Senior Lecturer, University College London; Consultant Cardiologist, The Heart Hospital and Barts Health NHS Trust, London, UK

Conference Topic: Session 7 - How to manage cardiac problems in the bone marrow transplant patient

Dr. Theresa McDonagh

Professor of Heart Failure and Consultant Cardiologist, King's College Hospital, London, UK

Co-Chair: Session 10 - How to deliver a successful cardio-oncology service

Dr. John McGowan

Clinical Research Associate and Hon. Cardiology Research Fellow, University College London Hatter Cardiovascular Institute, London, UK

Conference Topic: Session 10 - Training and Cardio-Oncology

Dr. Dragana Milojkovic

Consultant Haematologist, Hammersmith Hospital; Honorary Senior Lecturer, Imperial College London, London, UK

Conference Topic: Session 7 - BCR-Abl inhibitors and cardiovascular toxicity

Dr. Javid Moslehi, MD

Director, Vanderbilt Cardio-Oncology, Vanderbilt University Medical Centre, Nashville, TN, USA

founder

Dr. Moslehi is an Assistant Professor of Medicine and the Director of the Cardio-Oncology Program at Vanderbilt School of Medicine. He graduated from Johns Hopkins University and University of Connecticut School of Medicine. He then completed an internal medicine residency at Johns Hopkins Hospital.

Conference Topic: Session 2 - Cardiotoxicity caused by immunotherapy

Read More...

Following the completion of clinical cardiology fellowship at the Brigham and Women's Hospital and Harvard Medical School, he started a basic science post-doctoral fellowship at the Dana-Farber Cancer Institute focusing on the role of angiogenesis (formation of new blood vessels) in heart disease. In 2009, he founded the Cardio-Oncology program at Brigham and Women's Hospital/Dana-Farber Cancer Institute and Harvard Medical School with a clinic and research program focused on the cardiovascular care for cancer patients and cancer survivors. In 2014, he joined Vanderbilt. Dr. Moslehi is an expert clinician on the management of cardiac complications associated with radiation and both novel and traditional chemotherapies. His clinic and research program is focused on the mechanisms of toxicities associated with novel targeted therapies and how this knowledge can be modulated to understand human cardiovascular biology.

Dr. Kate Newbold

Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust, London, UK

Co-Chair: Session 9 - Arrhythmia management in cancer patients

Dr. Ann Partridge

Founder and Director, Program for Young Women with Breast Cancer; Director, Adult Survivorship Program; Senior Physician, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA

Conference Topic: Session 3 - Cardiovascular risk with chronic oestrogen suppression: is there a risk?

Dr. Juan Carlos Plana, MD

Chief, Clinical Operations of Cardiology, Department of Medicine, Baylor College of Medicine; Director, Cardio-Oncology Centre; Co-Director, Center for Advanced Cardiac Imaging, Baylor St. Luke’s Medical Centre, Houston, TX, USA

founder

Dr. Juan Carlos Plana Gomez  is Chief of Clinical Operations of the Section of Cardiology, Department of Medicine at Baylor College of Medicine, Director of the Cardio-Oncology Center, and co-Director of the Center for Advanced Cardiac Imaging at Baylor St. Luke’s Medical Center. He is the Don W. Chapman Chair in Cardiology and tenured Associate Professor of Medicine. Dr. Plana is board certified in Cardiology and Echocardiography.

Co-Chair: Session 2 - Immunotherapy ad Emerging Cardiotoxicity

Read More...

Dr. Plana earned his medical degree from Pontificia Universidad Javeriana, Santafé de Bogotá (Colombia). His extensive training included internship, residency, chief resident year and fellowship in Cardiovascular disease and Cardiac Imaging (echocardiography and Nuclear Cardiology) at Baylor College of Medicine. Dr. Plana’s academic career started at the University of Texas MD Anderson Cancer Center where he served as Director of Cardiac Imaging and Medical Director of the Echocardiography laboratory. In 2010, he was recruited to Cleveland Clinic, where he opened as served as Co-Director of the Cardio-Oncology center. Dr. Plana's clinical and research interests include Cardio-Oncology, valvular heart disease, diseases of the aorta, and advanced cardiac imaging. The major focus of Dr. Plana’s clinical and scholarly interest is the development and application of novel echocardiographic techniques in the early detection of cardiac dysfunction caused by chemotherapeutic agents. His work has led to 38 reports published in the peer-reviewed literature, as well as 8 invited reviews and book chapters. He authored the Expert consensus for multi-modality Imaging evaluation of cardiovascular complications of radiotherapy in adults, and more recently chaired the Expert consensus for the multi-modality Imaging evaluation of adult patients during and after cancer therapy: a joint effort of the American Society of Echocardiography and the European Association of Cardiovascular Imaging. His national and international stature in the field of Cardio-Oncology and cardiac imaging is reflected by his 122 invited presentations at national and international conferences; his invited service to 5 journal editorial boards (including his current service to the International Board of the Journal of Cardiovascular Echocardiography); and his invited service to, and leadership of multiple committees of the American Society of Echocardiography (for which he currently serves on the Board of Directors) and other professional societies (representing the United States on the Echocardiography Section of the Inter-American Society of Cardiology) , as well as to the NIH (NCI/NHLBI) (member of the Expert Panel on Cardio-toxicity) and the FDA. In addition to his scholarly efforts, Dr. Plana has been a dedicated educator, having received major teaching awards from BCM (Excellence in Teaching Award, 2000), M.D. Anderson Cancer Center (Teacher of the Year Award, Section of Cardiology, U. Texas Health Science Center, 2007), and the Cleveland Clinic (Teacher of the Year Award, Department of Cardiovascular Medicine, 2011).

Dr. Chris Plummer

Consultant Cardiologist, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Conference Topic: Session 9 - How and why to measure QT and what to do about it?

Dr. Ruth Plummer

Consultant Medical Oncologist, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Co-Chair: Session 2 - Immunotherapy ad Emerging Cardiotoxicity

Dr. Sanjay Prasad

Consultant Cardiologist, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom

Co-Chair: Day 1 Plenary Lecture

Prof. John Radford

Professor of Medical Oncology and Director of Research, The Christie Hospital; Molecular & Clinical Cancer Sciences University of Manchester, Manchester, United Kingdom

founder

John Radford is Professor of Medical Oncology and Director of Research at The Christie Hospital, Manchester. Research interests are focused on developing and testing new ways of treating lymphoma and monitoring the effectiveness of these treatments using novel biomarkers, studying late effects of chemotherapy on fertility, heart function and the risk of second cancers and investigating how best to prevent or minimise the impact of these in people cured of lymphoma. 

Conference Topic: Plenary Lecture - Long-term cardiovascular outcomes in survivors of Hodgkin's Lymphoma

Read More...

John is chair of the UK National Cancer Research Institute (NCRI) Lymphoma Clinical Studies Group, a member NCRI Hodgkin Lymphoma sub-group and chief investigator for many national and international trials.

Dr. Simon Ray

Consultant Cardiologist, The University Hospital of Manchester, Manchester, United Kingdom

Co-Chair: Session 5 - Coordinating Primary Care in Cardio-Oncology

Dr. Derek Rosario

Urologist, The University of Sheffield, Sheffield, UK

Conference Topic: Session 3 - Cardiac outcomes of ADT in prostate cancer

Dr. Stuart D Rosen, MA, MD, FRCP, FESC, FACC, FHFA

Consultant Cardiologist, Royal Brompton and London Northwest Healthcare Hospitals; Reader in Cardiology, National Heart and Lung Institute, Imperial College London; United Kingdom. Treasurer of the British Cardio-Oncology Society.

founder

Dr. Stuart Rosen is Consultant Cardiologist, Royal Brompton and London Northwest Healthcare Hospitals and Reader in Cardiology, National Heart and Lung Institute, Imperial College London; United Kingdom. He received his medical undergraduate education at Pembroke College, Cambridge and at Charing Cross and Westminster Medical School. His specialist cardiology training was at Charing Cross, Hammersmith and St Mary’s Hospitals.

Co-Chair: Session 3 - Hormonal Therapies and Cardiovascular Risk

Read More...

In clinical practice, Dr Rosen is a general adult cardiologist and has specialist expertise in heart failure, syncope and hypertension. His technical skills include transoesophageal echocardiography, stress echo, tilt testing and autonomic assessment, as well as ultrafiltration for decompensated heart failure. Dr Rosen had a pivotal role in setting up the UK’s first cardio-oncology unit, at the Royal Brompton Hospital, to provide bespoke care for patients at risk of cardiotoxicity or who have developed cardiac problems as a consequence of their anti-cancer treatment. He is Founding Treasurer of the British Cardio-Oncology Society. Dr Rosen has a programme of translational research focused on: Role of cardiac autonomic dysfunction in pathophysiology of cardiac disease; Origins of cardiac pain [member of an international task force on complex cardiac pain syndromes]; Mechanisms of heart injury in cancer patients. He is also cardiologist to the MRC’s Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial, a multi centre study of cardiovascular outcomes in prostate cancer patients treated with transcutaneous oestrogen patches compared with LHRH analogues. Dr Rosen has a busy managerial role as Clinical Director of Medicine at LNW Hospitals. He also has extensive teaching commitments, in medicine, cardiology, ethics and law for medical undergraduates and supervises postgraduates, MD and PhD students. Dr Rosen is author of more than 70 peer reviewed papers, plus review articles, editorials, abstracts, nine book chapters two books.

Dr. Douglas Sawyer, MD, PhD

Chief of Cardiac Services, Maine Medical Centre, Portland, ME, USA

founder

Dr. Doug Sawyer trained in medicine and cardiology at Brigham and Women’s hospital, and served on faculty at Boston University where he was a member of the BU Amyloid program, and subsequently at Vanderbilt University where he helped to found the Cardio-Oncology and Amyloid Programs.   Doug has been the Chief of Cardiac Services at Maine Medical Center in Portland Maine since 2014.

Conference Topic: Session 7 - Proteosomal inhibitors and cardiac complications

Dr. Christine Simmons, MD

Medical Oncologist, BC Cancer Agency, Vancouver, BC, Canada

founder

Dr. Christine Simmons is a Medical Oncologist at the BCCA Vancouver. She completed her residency training in Toronto, and completed a fellowship in Locally Advanced Breast Cancer at Princess Margaret Hospital in Toronto. She also completed a Master’s in Clinical Epidemiology at University of Toronto. She is a Clinical Assistant Professor at the University of British Columbia in the Faculty of Medicine.

Co-Chair: Session 3 - Hormonal Therapies and Cardiovascular Risk

Read More...

She is past Chair of the Locally Advanced Breast Cancer Canadian National Consensus group, and has a strong research interest in this area. In July 2014 she took on the role of Clinical Skills Course Director in the undergraduate medical program at UBC.

Prof. Roderick Skinner

Consultant in Paediatric and Adolescent Oncology/Bone Marrow Transplantation, Great North Children's Hospital, Royal Victoria Infirmary; Honorary Professor of Childhood Cancer, Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom

founder

Professor Rod Skinner has been a Consultant in Paediatric and Adolescent Oncology / BMT at the Great North Children’s Hospital, Royal Victoria Infirmary, Newcastle upon Tyne since January 1996, and is an Honorary Professor of Childhood Cancer, Northern Institute of Cancer Research, Newcastle University. He qualified in Birmingham in 1983, trained initially in general paediatrics and then in paediatric haematology/oncology and BMT in Newcastle, with further BMT experience in the Pediatric BMT Program, Minneapolis, USA. 

Co-Chair: Session 10 - How to deliver a successful cardio-oncology service

Read More...

He was awarded a PhD by Newcastle University in 1995 for his research thesis into chemotherapy-induced nephrotoxicity in children with cancer. He is the clinical lead in Newcastle for paediatric haematology allogeneic haemopoietic stem cell transplantation, long-term follow-up (LTFU), and bone marrow failure, and has a busy practice in paediatric / adolescent leukaemia. His research interests include late adverse effects of childhood cancer treatment, especially nephrotoxicity, and LTFU of childhood cancer survivors. He has played a leading role in the development of evidence-based, internationally-harmonised LTFU surveillance guidelines. He is a member of the UK Children’s Cancer and Leukaemia Group, with leading roles in the Late Effects Group (current chair), Supportive Care Group (chair 2003-08) and BMT Group (chair 2008-2012). He was a National Clinical Advisor in the NHS National Cancer Survivorship Initiative (2008-2012). He was one of the three instigators and founding members in 2008 of PanCare (Pan-European Network for Care of Survivors after Childhood and Adolescent Cancer), and remains on its Executive Board.

Prof. Ian Smith

Consultant Medical Oncologist, Professor of Cancer Medicine, Royal Marsden NHS Foundation Trust, London, United Kingdom

Conference Topic: Plenary Lecture - HER2 targeted therapies for breast cancer: New insights and cardiac safety

Dr. Susannah Stanway, MBChB, MRCP, MD, MSc

GCOS 2017 Co-Chair; Consultant in Medical Oncology, The Royal Marsden NHS Foundation Trust, London, United Kingdom

founder

Dr Susannah Stanway is a Consultant in Medical Oncology at The Royal Marsden NHS Foundation Trust. Having qualified from Bristol University in 1998, she obtained an MD thesis for her work on Steroid Sulphatase Inhibition in postmenopausal patients with Breast Cancer from Imperial College in 2009; her oncology training was undertaken at UCLH and The Royal Marsden NHS Foundation Trust. 

Co-Chair: Day 2 Plenary Lecture - The Global Epidemic of Cancer and Cardiovascular Disease

Read More...

She has been working at consultant level since 2012, both in the Acute Oncology Service at Croydon University Hospital and in the Royal Marsden NHS Foundation Trust’s Breast Unit. Along with actively recruiting patients to the large portfolio of research studies in the Breast Unit, her research interest is predominantly focused on Cancer Survivorship. This includes the area of cardio-oncology, in collaboration with amongst others, the Cardio-Oncology Group at the Royal Brompton Hospital and the London School of Hygiene and Tropical Medicine; treatment-induced Hot Flushes, where she sits on the NCRI Symptom Management Working Group; sexual and psychological consequences of cancer and has completed an MSc thesis on Risk Stratification to Guide Follow up after Childhood Malignancy. She co-chairs the Royal Marsden NHS Foundation Trust’s Living With and Beyond Cancer Committee; sits on the Royal Marsden Partners Survivorship pathway and has set up a pan-London multi-disciplinary survivorship research group; she leads the Living with and Beyond Cancer Module on the Institute of Cancer Research (ICR) MSc course; and has been actively involved with the Royal Marsden NHS Foundation Trust’s Young Women’s Breast Cancer Program since its inception; She has a personal interest in cancer control in low-middle income countries and she sits on the editorial board of ASCO’s Journal of Global Oncology, leads a sub-module on Cancer in Low-Middle Income Countries on the ICR MSc course and actively contributes to oncology education in East Africa with the Royal College of Physicians. She is immediate past president of the Oncology Section at the Royal Society of Medicine.

Prof. Justin Stebbing

Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College and Imperial College Healthcare NHS Foundation Trust, London, United Kingdom

Co-Chair: Session 8 - New Scientific Advances in Cardio-Oncology

Dr. Martin Štěrba, PharmD, PhD

Associate Professor and Deputy Head, Department of Pharmacology, Faculty of Medicine in Hradec Králové Charles University in Prague, Czech Republic

Conference Topic: Session 8 - Novel insights into mechanisms of dexrazoxane-mediated cardioprotection

Prof. Richard Sullivan

Director, Institute of Cancer Policy & Global Health, King's College London, London, United Kingdom

Conference Topic: Plenary Lecture - The Global Epidemic of Cancer and Cardiovascular Disease

Dr. Karen Syrjala

Co-Director of Survivorship Program, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA

Conference Topic: Plenary Lecture - e-Health and cardio-oncology

Dr. Sean A. Virani, MD, MSc, MPH, FRCPC

Associate Professor of Medicine, University of British Columbia; Provincial Heart Failure Lead, Cardiac Services BC, Vancouver, BC, Canada

founder

Dr. Virani is a key opinion leader for heart failure in Canada. He is founding Director of the Heart Failure Program at Vancouver General Hospital, Regional Director of Heart Failure Services for Vancouver Coastal Health/Providence Health Care, Heart Failure Physician Lead at Cardiac Services BC and Clinical Associate Professor of Medicine at the University of British Columbia.

Co-Chair: Plenary Lecture - The Global Epidemic of Cancer and Cardiovascular Disease

Read More...

He completed his internal medicine and cardiology training at UBC before embarking on a sub-specialization in heart failure and cardiac transplantation at Stanford University. He also has a Master’s degree in Public Health from Columbia University with a focus on healthcare management. His professional interests include public policy related to health care delivery with specific reference to healthcare systems redesign and quality in the Canadian context. Dr. Virani has authored a number of papers on chronic and acute decompensated heart failure and is a principal investigator on numerous research trials. He holds peer reviewed grant funding as a principal or co-investigator in excess of $1 million. He serves on the Provincial Advisory Committee for Cardiac Health, the executive of the Canadian Heart Failure Society, the Canadian Heart Failure Guidelines Committee and Co-Chairs British Columbia’s Specialist Services Committee.

Dr. Ashutosh Wechalekar

Senior Lecturer, Honorary Consultant Haematologist, University College London and Royal Free London NHS Foundation Trust, London, United Kingdom

Conference Topic: Session 7 - Modern advances in the treatment of cardiac amyloid

Dr. Ronald Witteles, MD

Associate Professor of Medicine, Internal Medicine Residency Program Director, Stanford University School of Medicine, Stanford, CA, USA

founder

Dr. Witteles leads Stanford University’s Cardio-Oncology clinic and is Co-Director of the Stanford Amyloid Center, one of the nation’s largest multidisciplinary groups devoted to amyloidosis. He earned his B.A. at Northwestern University followed by an M.D. with Honors from The University of Chicago Pritzker School of Medicine.

Conference Topic: Session 10 - How should we measure the quality of a cardio-oncology service?

Read More...

He then completed Internal Medicine residency at Stanford University (including an additional year as Chief Resident), followed by fellowship training in Cardiovascular Medicine (including serving as Chief Fellow). Following fellowship, Dr. Witteles joined the faculty at Stanford as a member of the Heart Failure team. Dr. Witteles founded Stanford’s Cardio-Oncology clinic and co-founded the Stanford Amyloid Center in 2008. He has led and collaborated on a multitude of clinical and translational research studies in Cardio-Oncology, amyloidosis, and cardiac sarcoidosis. His other primary role is as Program Director for the Stanford University Internal Medicine residency training program, in which he leads a program of 125 housestaff, and oversees all of the fellowship programs within the Department of Medicine.

Dr. Jay Wright

Lead Clinician for Heart Failure and Cardiac Devices, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, United Kingdom

Conference Topic: Session 9 - How to manage patients with cardiac pacemakers or defibrillators undergoing cancer surgery or thoracic radiotherapy?